A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies - Concepedia

Concepedia

Publication | Open Access

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

DOI Full Paper Access

95

Citations

24

References

2009

Year

Howard A. Burris, Charles W. Taylor, Suzanne F. Jones, Kevin M. Koch, M. Versola, Niki Arya, Ronald A. Fleming, Deborah A. Smith, Lini Pandite, Neil L. Spector,

Clinical Cancer Research

Abstract

Lapatinib was well tolerated following once and twice daily administration. Systemic exposure to lapatinib was dependent on the dose, duration and frequency of dosing, and prandial state. Clinical activity was observed.

References

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong, Science	1987	11.6K
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Journal of Clinical Oncology	1999	2.8K
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival Jennifer R. Grandis, Mona F. Melhem, William E. Gooding, JNCI Journal of the National Cancer Institute	1998	1.1K
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin José Baselga, David G. Pfister, Michael R. Cooper, Journal of Clinical Oncology	2000	743
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. David W. Rusnak, Karen Lackey, Karen Affleck, PubMed PathologyCell ProliferationCell GrowthTumor BiologyOncology	2001	737
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Wenle Xia, Robert J. Mullin, Barry R. Keith, Oncogene OncologyMedicineReceptor Tyrosine KinaseCancer BiologyDownstream Erk1/2	2002	664
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees, Journal of Clinical Oncology	2005	620
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg, Journal of Clinical Oncology	2002	577
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Valerie W. Rusch, José Baselga, Carlos Cordon‐Cardo, PubMed Lung InflammationPathologyPrimary NsclcGrowth Factor AlphaCancer Biology	1993	488

Page 1